Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aprea Therapeutics Inc (NQ: APRE ) 4.770 +0.163 (+3.54%) Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 5,197 Open 4.700 Bid (Size) 4.500 (6) Ask (Size) 4.800 (5) Prev. Close 4.607 Today's Range 4.500 - 4.770 52wk Range 2.780 - 8.847 Shares Outstanding 5,430,215 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial May 28, 2024 From Aprea Therapeutics Via GlobeNewswire APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 May 14, 2024 APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Performance YTD -4.60% -4.60% 1 Month -7.74% -7.74% 3 Month -34.12% -34.12% 6 Month +22.94% +22.94% 1 Year +39.88% +39.88% More News Read More Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update May 14, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference May 13, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics: Q4 Earnings Insights March 26, 2024 Via Benzinga Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 02, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 April 10, 2024 From Aprea Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session April 04, 2024 Via Benzinga APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 March 26, 2024 Via InvestorPlace Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update March 26, 2024 From Aprea Therapeutics Via GlobeNewswire Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday? March 11, 2024 Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session March 11, 2024 Via Benzinga Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million March 11, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers March 11, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 March 05, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor February 06, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 January 30, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 January 04, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update November 09, 2023 From Aprea Therapeutics Via GlobeNewswire A Look Into Healthcare Sector Value Stocks October 30, 2023 Via Benzinga Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways October 24, 2023 From Aprea Therapeutics Via GlobeNewswire Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio October 16, 2023 From Aprea Therapeutics Via GlobeNewswire 5 Value Stocks To Watch In The Healthcare Sector September 25, 2023 Via Benzinga 5 Value Stocks To Watch In The Healthcare Sector September 04, 2023 Via Benzinga Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman August 24, 2023 From Aprea Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
